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ABSTRACT
Objectives: To evaluate the efficacy of sentinel node biopsy (SNB) in oral squamous cell carcinoma (OSCC).
Design: A prospective study of a cohort of 25 consecutive patients with OSCC anatomopathological confirmation through 
biopsy, without oncological pre-treatment, in clinical stage T1-T4N0, of these 25 patients 14 were T1-T2N0. The absence 
of regional disease (N0) was determined by means of clinical exploration and cervical tomography (CT). To establish 
the overall sensitivity of the technique, a meta-analysis was carried out of 10 series published to February 2005 where 
SNB had been applied to head and neck cancer, adding our 14 T1-T2N0 cases, thus making a total of 260 patients.
Results:  Identification by SNB was accurate in 96% of the 25 cases, with a sensitivity of 66.7%. Analyzing only the 
T1-T2N0 cases (n=14), the accuracy was 100% with a sensitivity of 1 (CI 95%, 0.29-1.00). The overall sensitivity was 
93%. The accuracy in identifying the sentinel node varied between 66% and 100%. The SN was identified in 251 of 260 
cases, of those, 71 were true positive, 5 false negative and 175 true negative. The overall sensitivity was 93.4% (CI 95%, 
85.3-97.8), with a specificity of 100% (CI 95%, 0.98-100). The weighted negative probability quotient was 0.176 (CI 
0.103-0.301) and that of positive probability 24.75 (CI 95%, 10.8-56.71). The weighted diagnostic odds ratio was 183.71 
(CI 95%, 59.36-568.56). If  we accept that the prevalence of hidden regional disease is 30%, a negative sentinel node has 
5% possibility of having hidden disease.
Conclusions: Our data provide a certain degree of evidence that, due to its high sensitivity, the SNB procedure can be 
applied to the initial stages of OSCC.
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INTRODUCTION
The treatment of the oral squamous cell carcinoma (OSCC), 
and of head and neck cancer in general, when clinically 
presenting without regional disease (cNO) is controversial. 
Sentinel node biopsy (SNB) is a diagnostic technique that 
may contribute towards changing the management of this 
pathology. Accepted in breast cancer and melanoma, it 
remains to be validated in OSCC.
The prevalence of hidden regional metastasis in OSCC is 
considered to be around 30%. The most exact method of 
detecting hidden regional metastasis (cN+), is the anato-
mopathological study of the cervical lymph nodes, thus, 
radical cervical lymph node dissection, modified dissection, 
and in recent years even more selective dissections have been 
recommended.
Sentinel node biopsy can be considered the most selective 
dissection, since, theoretically, it would suppose the dissec-
tion of the first drainage node where a solid tumor metas-
tasizes. The validity of the concept is based on the fact that 
if  the sentinel node is free of metastasis, then other more 
distal nodes are also disease free. 
Following the first application of sentinel node biopsy in 
epidermoid carcinoma of the head and neck (1), Pitman 
(2) using vital dyes on sixteen patients did not identify any 
sentinel node. Koch (3) reported 60% success in identifi-
cation of the sentinel node using lymphoscintigraphy and 
intraoperative probes. Shoaib (4) carried out the sentinel 
node procedure with lymphoscintigraphy, intraoperative 
probes and vital dye, obtaining a high sensitivity. Other 
authors (5-6) established results in head and neck cancer, 
although in series of small samples; it being Shoaib (7) who 
presented results with a high sensitivity in a sample of 40 
cases of head and neck cancer.
Our objective is to offer clinical and statistical results of the 
technique, presenting our experience in stage T1-2N0 OSCC 
as well as a meta-analysis of the series of cases published 
until February 2005.
MATERIAL AND METHODS
In order to evaluate the efficacy of SNB and to determine 
the existence or otherwise of regional disease in OSCC, a 
prospective clinical study of a cohort of patients conse-
cutively diagnosed with OSCC by anatomopathological 
study was designed. The study was approved by the Ethical 
Board of our hospital and carried out in accordance with 
the Helsinki Declaration 1983. All the patients who agreed 
to enroll in the study were informed verbally and in writing, 
and signing an informed consent document.
The inclusion criteria included patients with primary OSCC 
of the oral cavity and oropharynx with anatomopatholo-
gical confirmation through biopsy of the lesion, without 
oncological pre-treatment, in clinical stage T1-T4 and with 
no clinical evidence of regional disease (N0). Twenty-five 
patients were recruited, 14 of whom were T1-T2 N0 (these 
14 cases are those included in the meta-analytical study). 
The absence of regional (N0) disease was determined by 
means of clinical exploration and cervical CT. Patients with 
relapses or who had had some type of previous treatment on 
the anterior cervical lymph node chains were excluded.
In our 25 cases, in order to facilitate identification of the 
sentinel node, the triple injection procedure with lymphoscin-
tigraphy, vital dye and gamma probe (Europrobe) was used. 
The day prior to surgery, the patients were infiltrated peri-tu-
morally at submucosal level with human colloidal seralbumin 
(Hazards, Nycomed Amersham-Sorin, Vercelli, Italy) labeled 
with 30-40 MBq 99Te, in 1 ml of saline serum.
Key words: Sentinel node biopsy, oral squamous cell carcinoma, cohort study, meta-analysis.
RESUMEN
 Objetivos: Evaluar la efectividad de la biopsia del ganglio centinela (BGC) en el carcinoma oral de células escamosas 
(COCE). Diseño: Estudio prospectivo, de una cohorte consecutiva de 25 pacientes con COCE confirmado anatomopa-
tológicamente mediante biopsia, sin tratamiento oncológico previo, en estadiaje clínico T1-T4N0, de estos 25 pacientes 
14 fueron T1-T2N0. La ausencia de enfermedad regional (N0) se determinó mediante exploración clínica y TC cervical. 
Para establecer globalmente la sensibilidad de la técnica se ha realizado un estudio con técnicas de metaanálisis de 10 
series publicadas hasta febrero de 2005, que han aplicado BGC en el cáncer de cabeza y cuello, a la que hemos sumado 
nuestros 14 casos T1-T2N0 lo que hace un total de 260 pacientes. Resultados: En los 25 casos la exactitud en la identifica-
ción del BCG fue del 96% con una sensibilidad del 66.7%. Si únicamente analizamos los casos T1-T2N0 (n=14), nuestra 
exactitud en la identificación fue del 100% siendo la sensibilidad de 1 (IC 95%, 0.29-1.00). La sensibilidad global fue del 
93%. La exactitud en la identificación del ganglio centinela varió entre el 66% y 100%. Se identifico el GC en 251 de 260 
casos, de los que 71 fueron verdaderos positivos, 5 falsos negativos y 175 verdaderos negativos. La sensibilidad global fue 
del 93,4% (IC 95%, 85,3-97,8) con una especificidad de 100% (IC 95%, 0,98 -100). El cociente de probabilidad negativo 
ponderado fue de 0,176 (IC 0,103-0,301) y el de probabilidad positivo fue de 24,75 (IC 95%, 10,8- 56,71). La odds ratio 
diagnóstica ponderada fue de 183,71 (IC 95%, 59,36-568,56). Si aceptamos que la prevalencia de enfermedad regional 
oculta es del 30%, un ganglio centinela informado como negativo tiene un 5% de posibilidades de tener enfermedad 
oculta. Conclusiones: Nuestros datos aportan un cierto nivel de evidencia que el BGC es un procedimiento que por su 
elevada sensibilidad, puede ser aplicada en los estadios iniciales del COCE.
Palabras clave: Biopsia ganglio centinela, carcinoma oral de células escamosas, estudio de cohortes, metaanálisis.
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The patient was immediately transferred to the nuclear 
medicine service where a static lymphoscintigraphy was 
carried out, marking the position of the identified sentinel 
node on the skin. (Fig. 1) Eighteen hours later, and with 
the patient already anesthetized, 1 ml of blue dye (Patent 
Blue V, Guerbet laboratories, Cedex, France) was infiltrated 
in the same points. The sentinel nodes were located using 
a gamma probe, and identified by level. Once the sentinel 
node or nodes had been extracted, an elective dissection of 
stages I-II-III (supraomohyoid) or modified radical type III 
(levels I to V) was made as control in those cases where the 
lymphoscintigraphy showed involvement at lower levels.
The anatomopathological examination of  the cervical 
dissection specimens was carried out via bi-dissection. In 
the case of a sentinel node the multi-section technique was 
carried out and in negative cases immunohistochemical 
techniques for cytokeratin were carried out.
The second part of our study is a meta-analysis of an inde-
pendent review of ten series published to February of 2005 
(5,6,8-15) on sentinel node biopsy applied to head and neck 
cancer. Each of the series included more than fifteen cases. 
In addition, the 14 T1-T2NO cases of our study were also 
included in the analysis. The Cochrane, Database and ME-
DLlNE databases were used to select the series for the meta-
analytical study. In those cases where an article, could not be 
accessed, the principal investigator was contacted. Complete 
information was not obtained for three published articles 
(16-18), thus forcing their exclusion from the study.
Series containing homogeneous information for comparison 
and sufficient data to extrapolate only cases T1-T2 were 
selected. All the series used lymphogammagraphy prior to 
the surgical intervention and intraoperative radio-localiza-
tion using a gamma probe. Six of the series (5,6,8-10,14) 
used vital dye.
All the series used an elective cervical or supraomohyoid, 
or radical modified type III dissection as control. Ross (9) 
carried out radical dissection as control. The follow up of 
the patients varied between 9 and 32 months.
Regarding the statistical analysis, basing ourselves on the 
Bayes theorem, instead of providing predictive values for 
each individual study, we have preferred to show probability 
quotients that operate more efficiently in the diagnostic 
probability calculations. For each individual study we have 
calculated the following diagnostic values: sensitivity, posi-
tive probability quotient, negative probability quotient and 
diagnostic odds ratio, with a confidence interval of 95%.
The sum of the ROC curve was used to estimate the general 
accuracy of SNB. The study was carried out using the ‘Me-
tadisc’ program (Meta-analysis of diagnostic and screening 
tests. Zamora J, Muriel A, Abraira V. Clinical Biostatistics 
Unit. Hospital Ramón y Cajal, Madrid).
RESULTS
Our series consists of 25 consecutively-enroled patients with 
OSCC stages T1-T4NO and to whom the sentinel node 
technique was applied between January 2001 and Novem-
ber 2002. Of the 25 patients, 14 were T1-T2NO and were 
included in the meta-analysis. The mean age was 65.9 years, 
SD=13.7. The male/female ratio was 17/8. The location of 
the primary lesion is described in Table 1. As control, a total 
of 28 selective cervical dissections were carried out (in three 
patients a cervical bilateral dissection was carried out due 
to the proximity of the primary tumor to the mid line and 
bilateral lymph node marked in the lymphoscintigraphy.
In 19 of the 25 cases, control of the stage of the cervical 
disease was made by selective dissection of the node levels 
I-II-III,and in six cases levels IV-V were included because 
the sentinel node was identified at those levels in the lym-
phogammagraphy.
SNB in our series was effective in 24 of 25 cases, accura-
tely identifying the sentinel node in 96% of the cases. The 
technique could not be applied in one case as it was not 
possible to locate the sentinel node, so an elective cervical 
dissection was made, and the case was not included in the 
statistical analysis.
One or more sentinel nodes were identified, with an average 
of 3.2 per patient. The average length of the procedure, from 
the moment of incision to obtaining the sentinel node, was 
between 30 and 45 minutes.
Table 2 details the positive cases, location and distribution of 
the sentinel node by level, both positive and negative, the num-
ber of cases and areas of positive drainage. Of the 6 positive 
nodes, 2 were in level I, 2 in level II and the other 2 in level III. 
We did not find any positive sentinel node in levels IV - V.
The lymphoscintigraphy demonstrated that 5 (20.8%) of our 
cases had bilateral drainage. One of these, lingual, T1, pre-
sented bilateral positive sentinel nodes, an ipsilateral node in 
level I and two nodes with disease (N+)on the contralateral 
side in level III. Of the five cases with bilateral drainage to 
our tracers one was positive to disease, meaning that 20% 
of our cases with bilateral drainage presented contralateral 
metastasis. We identified another three cases in our series 
with drainage at unexpected node levels, without invasion 
node levels I-II. Two cases of primary tumors located in the 
anterior lingual third at stage T1 and one case in the gingiva 
at stage T1. These eight cases with unexpected drainage 
constitute 33.3% of our series.
Fig. 1. Marking the position of the identified sentinel 
node on the skin.
E238
Med Oral Patol Oral Cir Bucal 2007;12:E235-43.                                                                � Sentinel node in head and neck cancer                                                         Med Oral Patol Oral Cir Bucal 2007;12:E235-43.                                                                  � Sentinel node in head and neck cancer
Author / N 
nº patients
Primary 





















100% 3 1 13 
75%
(19 - 99) 
0,311
(0,08 - 1,19) 
63






Tongue MRND III 
39/41
































38 ``wait & see´ 
61/61












I-II-III and II to IV 
11/13

























Selective, Levels     
I-II-III and  II to IV 
14/14











Elective, I-II-III or 
I-II-III-IV
14/15











































I to IV 
14/14















214 / 223 









Patient  Age / Sex Location cTN0 Nº of SN Location (level) Level of positive SN 
1 53/H Oropharynx 4 4 I-II-IV-V - 
2 32/H Anteriorlingual 1 4 Ic-I-II-III - 
3 80/M Anteriorlingual 2 2 I-II - 
4 88/M Anteriorlingual 1 3 IIIx3 - 
5 64/H Gingiva 1 3 I-IIIx2 - 
6 54/H Anteriorlingual 3 4 I-II-IIIx2 - 
7 71/H Anteriorlingual 1 4 IIx3-V - 
8 54/H Floor of mouth 2 4 I-Ic-II-V - 
9(1) 70/H Trigone 2 - - - 
10 70/H Anteriorlingual 3 3 IIx3 - 
11 34/H Anteriorlingual 2 4 I-IIx2-V I 
12 73/H Anteriorlingual 2 4 I-IIIx3 - 
13 66/M Trigone 1 2 I-II - 
14 47/H Floor of mouth 1 1 II - 
15 48/M Anteriorlingual 1 4 I-IIx2-III - 
16 74/H Jugalmucosa 2 2 I-II - 
17 62/H Jugalmucosa 1 2 I-II II 
18 80/H Anteriorlingual 1 4 I-II-IIIcx2 II-IIIcX2 
19 73/M Palate 4 1 I I 
20(2) 75/M Posterior lingual 3 - - - 
21 78/H Floor of mouth 3 8 II-IIc-IIIx3-IIIc x3 - 
22 65/M Gingiva 4 4 I-IIx3 - 
23(3) 72/M Jugalmucosa 3 - -  
24 69/M Posterior lingual 3 2 I-III - 
25 67/M Gingiva 4 3 IIx2-Ic - 
(1) Technique not applicable.
(2) False negative. We consider an adenopathy at level V as a negative sentinel node. The cervical dissection revealed a 
positive adenopathy at level III.
(3) False negative. Negative sentinel node, positive adenopathy at level I of the cervical dissection.
Table 1. Description of cases with their location, clinical stage, cervical levels explored with the position of the sentinel 
node. 
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Level I Level II Level III Level IV Level V 
Nº of 
positive SN 
Anterior lingual 2/10 3/10 (1) 1/8 1/14 2/12 0/0 0/2 4/36 
Posterior lingual 0/1 0/1 0/1  0/1   0/2 
Jugal mucosa 1/2 1/2 0/2 1/2    1/4 
Palate 1/1 1/1 1/1     1/1 
Floor of mouth 0/3 0/5 0/2 0/4 0/6  0/1 0/13 
Trigone 0/1 0/1 0/2    0/2 
Oropharynx 0/1 0/1 0/2   0/1 0/1 0/4 
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   (1): Nanocoll (2): Albures. (3) microcolloid  (4) sulfur colloid ENT: Oral, oropharynx, larynx and hipopharynx. 
*1 case with no captation, where the technique is not applicable was positive to disease. †One case without detectable sentinel nodes out of 3 contained 
disease at the neck dissection.
Table 3.  Meta analysis of T1-T2 cases. 
Table 2. Distribution sentinel nodes by level. Percentages. 
(1): One patient presented one ipsilateral and two contralateral sentinel nodes, all positive.
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Fig. 2. The negative probability quotient was 0.37 (CI 0.14-0.999). 
Fig. 3. The negative weighted probability quotient is 0.176 (CI 0.103-0.301). 
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Of the 24 cases included in our series, 18 turned out to be 
true negative, four true positive cases and 2 false negative 
cases. This represents a sensitivity of 66.6%for the technique 
(CI 0.22-0.96) and a specificity of 1 (CI 0.81-1).
The negative probability quotient was 0.37 (CI 0.14-0.999) 
(Fig. 2) and the positive 24.43 (CI 1.5-397.83). The diag-
nostic odds ratio was 66.6 (CI 2.6-1644.3).
Four nodes (16%), clinically considered as N0 before the 
intervention, revealed hidden micrometastases diagnosed by 
immunohistochemistry and not by anatomopathological bi-
dissection. (Table 2). Of these two false negatives, one was a 
tumor (T3) at the base of the tongue, where a sentinel node 
was indicated as negative in level V and the control cervical 
dissection contained a positive node in level III. 
The second case was in the jugal mucosa (T3) where a node 
of 10mm in diameter (obtained in level I) did not take up 
either radiotracer, or dye and was given as positive. Both 
the cervical dissection and the two sentinel nodes obtained 
were indicated as negative to disease.
Lymph node metastases were found in levels I, IIA, IIIA 
and IIIB, however the nodes obtained in levels IV and V 
were disease free. (Tables 1 and 2)
Regarding the meta-analysis, ten series published (5,6,8-15) 
on sentinel node biopsy in epidermoid carcinoma of head 
and neck were included in addition to our series. All the 
series included more than 15 cases, comprising a total of 260 
SNB procedures. The basic descriptive information of the 
series is shown in Table 3, including our 14 T1-T2 cases.
From the analysis of these series, a similar incidence of false 
negatives can be deduced. We did not find any significant 
differences between the series that analyze cases in initial sta-
ges T1-T2 and those that include cases T1-T4 (p>0.05).
The accuracy of the technique in identifying the sentinel node 
varies between the 66 and 100%, with 251 of the 260 cases 
identified (96.5%). The results show 71 true positive cases, 5 
false negatives and 175 true negative cases. This constitutes 
an overall sensitivity for the technique of 93.4% (CI 85.3-
97.8) with a specificity of 100%, (CI 0.98-100). The negative 
weighted probability quotient is 0.176 (CI 0.103-0.301). (Fig 
3). The positive probability quotient is 24.75 (CI 10.8-56.71). 
The weighted diagnostic odds ratio is of 183.71 (CI 59.36-
568.56). No statistically significant evidence exists (p=0.16) 
for the threshold effect shown in the regression curve by 
Moses (19,20). In Fig 3 it can be seen that the area under the 
ROC curve was 0.989 (standard error 0.0059).
DISCUSSION
Although diagnostic tools have developed significantly, we 
have no effective procedures available to identify hidden 
metastatic disease in the cervical lymph nodes of patients 
with OSCC. The incidence is situated at around 30%, a high 
percentage, and the presence of regional disease is the cause 
of the death of one of every two patients. (21, 22).
The recommendation to carry out an elective cervical dis-
section when the probability of hidden cervical metastasis 
is higher than 20% persists (23-25), for this reason the use 
of elective dissections and its variants is common practice 
in the staging of regional disease in OSCC (26-32).
Analyzing less invasive procedures, the application of SNB has 
been demonstrated to be very useful in other types of cancer 
(33,34) and for this reason we have studied its application in 
primary OSCC, presenting the results of a series of 25 patients 
and a meta-analytical study, in an attempt to determine if SNB 
is a useful technique in the diagnosis of regional metastasis.
In our series it was possible to apply the technique in 96% 
of the patients, a very similar percentage to other contrasted 
series. The technique is quickly applied in comparison with 
cervical staging dissections.
It remains to be determined if  the absence of lymphatic 
drainage, demonstrated by a lymphoscintigraphy has any 
diagnostic significance in itself, since it could indicate some 
blockage of the lymphatic system by the disease.
We center the present study on T1-T2 cases aiming to priori-
tize the homogeneity of the study. Our results do not reveal 
any heterogenetic significance in the diagnostic indicators 
among the studies analyzed in these cases.
The overall sensitivity of 93.4% with a negative probability 
quotient of 0.176% makes sentinel node biopsy a diagnostic 
tool able to substantially reduce the uncertainty over regio-
nal staging, demonstrating a DOR of 183.71 with an area 
under the curve of 0.989. Instead of providing predictive 
values, we have preferred to show probability quotients, since 
the former are strongly dependent of the prevalence of the 
disease and the latter allow a more simple application of 
the Bayesian theory of diagnostic probability estimation. 
Supposing an estimation of 30% hidden metastasis (the 
general prevalence in our study is 24.8%), the post-test pro-
babilities would be 88% for a positive test result and almost 
5% for a negative test result. This supposes that a sentinel 
node biopsy, when technically possible could significantly 
alter the diagnosis in cases without clinical regional disease, 
since the possibility of hidden disease with a negative test 
result is lower than 5%.
SNB revealed hidden metastasis in four of the cases consi-
dered clinically to be free of disease, equal to 16% of our 
series. (Table 1) Two of these cases being identified by immu-
nohistochemistry only. If  we consider the results obtained 
only by anatomopathological bi-dissection, we would have 
improved the staging in only two cases (8% of cases). This 
is another of the benefits to be gained from the application 
of the sentinel node concept.
Another advantage supposes the possibility of  applying 
advanced anatomopathological study techniques to a very 
reduced number of lymph nodes (72 sentinel nodes in 22 
patients with a mean of  3.2 per case), against an entire 
regional dissection, usually with more than 10 nodes, thus 
allowing an increase in the staging sensitivity. Our results are 
similar to those of Van Brekel (35) and Czerniecki (36) who 
using multi-slicing techniques and immunohistochemistry 
find optimized positive sentinel node identification in 21% 
and 10% of cases respectively.
Among those factors that may influence the sensitivity of 
the anatomopathological study of these adenopathies are 
those attributable to errors in taking the sample which will 
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depend on the size and location of the metastasis, the size 
of the adenopathy, on the orientation within their section 
and on the number of sections evaluated.
A recent multicenter study (37), in which we took part, 
shows that applying immunohistochemical procedures in 
SN optimizes staging by 17%, (59/348) against 6% (67/1180) 
if  the anatomopathological study is carried out using bi-
dissection and hematoxylin-eosin staining.
Ross (9) using multi-section techniques and immunohistoche-
mical marking, identified hidden metastasis in 5 of 27 patients 
(19%), the other 22 patients were confirmed with standard 
bi-dissection techniques and hematoxylin-eosin staining.
These data suggest that multi-section and immunohisto-
chemical techniques should be applied systematically in 
SN, since they significantly increase the sensitivity of the 
anatomopathological study. Another subject to mention is 
the cervical drainage pattern of the metastasis: is it predic-
table? In the lymphoscintigraphy, 12.5% (3/24) of our cases 
that did not involve the mid-line presented bilateral drainage. 
We found another three cases in our series with drainage 
in unexpected lymph node levels, in that the node stages 
I-II were skipped. These unexpected drainages constituted 
20.8% of our cases. With these data one might ask if  the 
lymphatic route of regional metastasis in OSCC is predicta-
ble. Kowalski (38) in a review of 513 patients found that in 
high risk patients the possibility of presenting contralateral 
metastasis is greater than 20%. Byers (39) in a review of 
lingual tumors at stage T1 to T2 found 16% of cases with 
an unpredictable or disordered drainage and were defined 
as “skip metastases” and which we have named jump me-
tastases. Other authors such as Woolgar (40) found a 10% 
incidence in 154 patients.
Why does this occur? Do aberrant lymphatic canals or paths 
exist that become permeable under special circumstances? 
Among the possible answers it has been suggested that a 
primary tumor drains to a node defined by the immune 
system. It is not clear if the tumor cells stimulate the immune 
system inside the lymph nodes, increasing the uptake of 
the metastatic cells, or if  they do this by suppressor T cells 
induced by the tumor that limit the action of the cytotoxic T 
cells, allowing the implantation of the metastatic cells in the 
lymph nodes. Schuller (41) attempting to evaluate regional 
immunity in head and neck cancer, put lymphocytes extrac-
ted from the same patient’s lymph nodes in contact with the 
tumor and observed that the immune system is regionally 
active. Is it the metastatic node that activates the response or 
is this immunostimulated by the tumor? This same author 
(42) with non-specific stimulants of  the immune system 
found an intrinsic response from the lymph node. Chu (43) 
suggests that the tumor stimulates the T helper lymphocytes 
through antigen carrier cells that circulate from the tumor 
toward the lymph node containing the antigen-specific T 
cells (the sentinel node).
Cochran (44) demonstrates a reduction in the paracortical 
area, and of dendritic cells in sentinel nodes in melanoma 
resulting from immunosuppression factors liberated by the 
tumor. These data suggest more an immune and histopatholo-
gical justification of the sentinel node concept than the classic 
system of stratified lymph node stations that would partly ex-
plain the so-called “skip metastases” or “jump metastases”.
CONCLUSIONS
Our study contributes a certain degree of  evidence that 
in T1-T2N0 OSCC, SNB should be considered a highly 
sensitive diagnostic procedure, thus it is a valid alternative 
to elective stage dissection. It reduces both time spent in 
surgery and postoperative morbidity. The technique should 
be carried out using lymphoscintigraphy, vital dye and an 
intraoperative gamma probe.
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